Dr. Carla Grandori is an internationally recognized physician-scientist who pioneered new technologies to develop the next generation of cancer therapeutics tailored to each individual’s tumor. Dr. Grandori’s entrepreneurial experience and network drove the growth of SEngine Precision Medicine. She has recruited a world-class team including a Nobel Prize Laureate and a Pulitzer Prize-winning oncologist. Dr. Grandori raised seed and Series A funding for SEngine Precision Medicine to enable CLIA certification for SEngine’s high-throughput test, the PARIS® assay, guiding cancer treatment options. This funding enables the development of therapies targeting previously undruggable oncogenes including MYC, KRAS and TP53. The oncology startup is accelerating drug discovery and functional precision medicine to transform cancer care. Dr. Grandori received her MD from the University of Rome and Ph.D. from the Rockefeller University in New York. The majority of her scientific career was at the Fred Hutchinson Cancer Research Center in Seattle.
For nearly a decade, non-profit Cancer Commons has helped thousands of patients and their physicians beat the odds with information about the latest tests and treatments. New software and industry partnerships are taking this to the next level, where treatment decisions are in-formed by the latest tech, a treatment’s accessibility, and the collective experience of all patients and physicians.